Breakthrough in Lupus Treatment: Fate Therapeutics Initiates First-of-its-Kind CAR-T Cell Study
![Fate Therapeutics logo](https://nationalstemcelltherapy.com/wp-content/uploads/2022/12/fate-therapeutics-logo.jpg)
In a significant advancement in the treatment of autoimmune diseases, Fate Therapeutics has announced the commencement of a pioneering clinical study targeting systemic lupus erythematosus (SLE), commonly known as lupus. This marks the first time a patient with lupus has been treated using an “off-the-shelf” chimeric antigen receptor (CAR) T-cell therapy, a groundbreaking approach that […]
Beam’s Breakthrough: Revolutionizing Genetic Medicine?
![Beam Therapeutics logo](https://nationalstemcelltherapy.com/wp-content/uploads/2022/11/beam-therapeutics-logo-1024x525.jpg)
Beam Therapeutics Inc., a leading biotechnology company specializing in precision genetic medicines through base editing, has recently made a significant announcement. In August, the company initiated treatment for its first patient with BEAM-201, a quadruplex-edited allogeneic CAR-T cell investigational therapy. This therapy is currently under evaluation in a Phase 1/2 clinical trial aimed at treating […]